Engineers Gate Manager LP increased its position in Cerus Co. (NASDAQ:CERS – Get Rating) by 52.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 122,884 shares of the biotechnology company’s stock after purchasing an additional 42,432 shares during the quarter. Engineers Gate Manager LP owned approximately 0.07% of Cerus worth $442,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently modified their holdings of the company. Mackenzie Financial Corp raised its holdings in shares of Cerus by 3.0% in the 2nd quarter. Mackenzie Financial Corp now owns 78,624 shares of the biotechnology company’s stock valued at $416,000 after purchasing an additional 2,264 shares during the period. Lazard Asset Management LLC raised its holdings in Cerus by 2.8% in the 3rd quarter. Lazard Asset Management LLC now owns 161,227 shares of the biotechnology company’s stock valued at $580,000 after acquiring an additional 4,352 shares during the period. Rice Hall James & Associates LLC raised its holdings in Cerus by 1.0% in the 3rd quarter. Rice Hall James & Associates LLC now owns 572,362 shares of the biotechnology company’s stock valued at $2,061,000 after acquiring an additional 5,500 shares during the period. Goldman Sachs Group Inc. raised its holdings in Cerus by 1.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 426,744 shares of the biotechnology company’s stock valued at $2,343,000 after acquiring an additional 6,863 shares during the period. Finally, ExodusPoint Capital Management LP raised its holdings in Cerus by 3.8% in the 2nd quarter. ExodusPoint Capital Management LP now owns 233,339 shares of the biotechnology company’s stock valued at $1,234,000 after acquiring an additional 8,516 shares during the period. 82.47% of the stock is owned by institutional investors.
Cerus Stock Up 0.7 %
Shares of CERS opened at $2.80 on Monday. Cerus Co. has a 12 month low of $2.36 and a 12 month high of $5.95. The firm’s 50 day moving average is $3.07 and its 200-day moving average is $3.56. The stock has a market capitalization of $497.34 million, a PE ratio of -11.20 and a beta of 0.97. The company has a current ratio of 1.45, a quick ratio of 1.21 and a debt-to-equity ratio of 0.20.
Analyst Ratings Changes
Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E.
- Get a free copy of the StockNews.com research report on Cerus (CERS)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.